ABBV

Executive Summary

Investment Thesis

AbbVie has successfully navigated the Humira patent cliff and is now firmly in growth mode. Q1 2026 revenue surged 12.4% to $15.0 billion, driven by the immunology powerhouse duo of Skyrizi ($4.5B, +32.5%) and Rinvoq ($2.1B, +29.5%). Combined, these two drugs are running at a $26B+ annual rate and are expected to reach $31.8B in FY2026.

Management raised full-year 2026 guidance to $67.3B in revenue and adjusted EPS of $14.08–$14.28, representing a 42% EPS rebound from the FY2025 trough of $10.00. Beyond immunology, AbbVie's neuroscience portfolio exceeded $10.7B in FY2025, and the oncology segment is approaching $7B.

AbbVie is a Dividend King with 52 consecutive years of dividend increases (including the Abbott Labs legacy). The current yield of 3.26% ($6.92/share) is supported by ~$20B in annual free cash flow. The $67.5B debt load from the Allergan acquisition is being steadily reduced, with debt/EBITDA now at 2.8x.

Verdict: AbbVie offers a rare combination of growth + income in large-cap pharma. At 15x forward earnings with a 3.26% yield and double-digit EPS growth, the risk/reward is compelling. Buy with a probability-weighted 12-month target of $248.

Growth Drivers

Key Growth Catalysts

$31.8B Combined FY2026E Revenue

Skyrizi + Rinvoq Dominance

Skyrizi (IL-23 inhibitor) is on track for $21.6B in 2026, growing 30%+ across psoriasis, psoriatic arthritis, and Crohn's disease. Rinvoq (JAK inhibitor) targets $10.2B across rheumatoid arthritis, atopic dermatitis, and ulcerative colitis. Together they have more than replaced lost Humira revenue.

$10.7B FY2025 Revenue; Growing Platform

Neuroscience Franchise

Led by Botox Therapeutic, Vraylar, and Qulipta. Botox remains the #1 neurotoxin globally. Vraylar expanding in bipolar depression and schizophrenia. Emraclidine (muscarinic agonist) is a high-potential pipeline asset for schizophrenia with differentiated mechanism of action.

52 Years of Consecutive Dividend Increases

Dividend King + FCF Machine

Annual dividend of $6.92/share (3.26% yield) with 5-year CAGR of 6.3%. ~$20B annual free cash flow covers the ~$12.3B dividend obligation 1.6x. Payout ratio on adjusted EPS ~49%. Debt deleveraging on track with $5.3B cash on hand.

2026-04-25

Q1 2026 Earnings Release

Revenue $15.0B (+12.4% YoY). Adjusted EPS $2.65 (+7.7%). Raised FY2026 guidance to $67.3B revenue and $14.08–$14.28 adjusted EPS. Skyrizi $4.5B (+32.5%).

2026-05-15

Q2 2026 Dividend Payment

$1.73/share quarterly dividend paid. Ex-dividend date was April 15. Next ex-dividend expected mid-July 2026.

2026-07-25

Q2 2026 Earnings (est.)

Consensus revenue ~$16.5B. Adjusted EPS consensus ~$3.50. Key focus: Skyrizi trajectory toward $21.6B FY target, Rinvoq momentum, aesthetics recovery signals.

2026-09-30

IRA Drug Negotiation Updates

CMS continues Medicare drug price negotiations under the Inflation Reduction Act. Imbruvica already subject to negotiated pricing. Watch for potential expansion to additional AbbVie drugs in future negotiation cycles.

2027-01-31

Q4 2026 / FY2026 Earnings (est.)

Full-year results will validate the $67.3B revenue and $14.18 EPS guidance. Key test: did Skyrizi + Rinvoq achieve $31.8B combined? Does management signal FY2027 growth above consensus?

Earnings & Signals

Forward Estimates, Surprises & Insider Activity

Forward Earnings Estimates

Earnings Surprise Track Record

Q1 2026 Est: $2.55 Act: $2.65 +3.9%

Q4 2025 Est: $2.60 Act: $2.71 +4.2%

Q3 2025 Est: $1.80 Act: $1.86 +3.3%

Q2 2025 Est: $2.85 Act: $2.97 +4.2%

Q1 2025 Est: $2.38 Act: $2.46 +3.4%

Q4 2024 Est: $2.80 Act: $2.91 +3.9%

Insider Activity (90 Days)

Net Buying/Selling-$12.4M net (routine 10b5-1 plans)

Sell/Buy RatioN/A

N/A

Peer Comparison

Relative Valuation vs. Competitors

Company	price	marketCap	revenueTTM	revenueGrowth	forwardPE	evRevenue
AbbVie Inc.	212.51	375B	63.4B	12.4%	15.1	7
Johnson & Johnson	168.5	405B	88.8B	5.2%	15.8	4.9
Eli Lilly & Co.	920	875B	48.5B	36%	42	18.5
Merck & Co.	128	324B	62.5B	4.8%	12.5	5.5
Bristol-Myers Squibb	58	117B	47.2B	2.1%	8.5	3.5

ABBV trades at a modest premium to pharma peers (15x vs. MRK 12.5x, BMY 8.5x) justified by superior revenue growth (12.4% vs. peer median ~5%) and its Dividend King status. LLY commands a massive premium on GLP-1 growth. AbbVie offers the best growth-income balance in the group.

Valuation

Price Targets & Scenarios

Scenario	Price Target	Assumptions	Probability
Bull Case	$290	Skyrizi and Rinvoq exceed $35B combined by FY27. Aesthetics recovery accelerates. Pipeline delivers with emraclidine (schizophrenia) and oncology assets. Humira erosion bottoms out. P/E re-rates to 18–20x forward earnings on durable growth visibility. Dividend King premium sustained.	25%
Base Case	$250	AbbVie delivers on $67.3B revenue and $14.18 EPS guidance. Immunology franchise grows 15–20% led by Skyrizi ($21.6B) and Rinvoq ($10.2B). Humira declines stabilize. Neuroscience and oncology provide mid-single-digit portfolio growth. Dividend grows 5–6%. Stock trades at 16–17x forward P/E.	50%
Bear Case	$180	Humira erosion accelerates beyond expectations. Skyrizi or Rinvoq face unexpected competition or safety signals. IRA drug pricing negotiations create revenue headwinds. Aesthetics remains soft. Debt load limits M&A flexibility. P/E compresses to 12–13x on earnings quality concerns.	25%

Probability-Weighted Target: $247.50 (+16.5%)

$247.50

Weighted

Bull $29025%

Base $25050%

Bear $18025%

Analyst Consensus

Morgan Stanley

Goldman Sachs

BMO Capital Markets

Barclays

17 Buy, 7 Hold, 0 Sell

Risk & Ownership

Risk Assessment & Insider Signals

!Risk Factors

Humira Biosimilar Erosion Acceleration: Humira revenue declined 25.9% in Q1 2026 to $1.25B. While declines are expected, faster-than-modeled erosion could pressure near-term earnings. Multiple biosimilar competitors are gaining formulary positions. Humira is still ~8% of total revenue.
IRA Drug Pricing / Legislative Risk: Imbruvica is already subject to Medicare price negotiations. Skyrizi and Rinvoq could eventually face negotiation in future cycles. Broader legislative action on drug pricing remains a persistent overhang for the entire pharma sector.
Immunology Competition: Skyrizi faces competition from other IL-23 inhibitors and emerging therapies in psoriasis and IBD. Rinvoq (JAK inhibitor) carries black box warnings that limit some prescribing. New entrants in autoimmune space could slow growth trajectories.
Aesthetics Segment Weakness: Botox Cosmetic and Juvederm continue to face macro headwinds from reduced consumer discretionary spending. Aesthetics revenue was ~$1.3B in Q4 2025, still below pre-COVID trajectory. Recovery timing uncertain.
Debt Load & Balance Sheet: Total debt of $67.5B and negative shareholder equity are legacies of the $63B Allergan acquisition. Interest coverage is 8x EBIT, adequate but not robust. Rising rates increase refinancing costs. Limits strategic M&A flexibility.
Pipeline Execution Risk: Long-term growth beyond Skyrizi/Rinvoq depends on pipeline success in neuroscience (emraclidine) and oncology. Clinical trial failures or regulatory delays could undermine the post-2030 growth narrative.

OOwnership & Insider Signals

Vanguard Group: 10.15% | 179.7M shares | Institutional
BlackRock Inc.: 8.20% | 145.1M shares | Institutional
State Street Corp.: 4.85% | 85.9M shares | Institutional
Capital Research Global: 3.40% | 60.2M shares | Institutional
Insiders: 0.16% | 2.8M shares | Insider
Retail & Other: 24.8% | ~439M shares | Retail

Recommendation

Summary

Price

$212.51

12mo Target

$252 (consensus)

Upside

+18.6%

Rating

BUY

Div Yield

3.26%

Forward P/E

15.1x

Entry Strategy

40% — Buy at Current Levels

$210–$215

Above both moving averages with bullish momentum. 3.26% yield provides income while waiting. 15x forward P/E is reasonable for a Dividend King.

35% — Add on Pullback

$197–$205

Near 200-DMA support (~$207) or April low (~$197). Yield would approach 3.5%. Better risk/reward entry with ~25% upside to bull target.

25% — Add on Q2 Beat / Breakout

$220–$230

If Q2 earnings confirm full-year trajectory and stock breaks above $220 resistance. Willing to pay up for de-risked growth confirmation.